Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ixabepilone plus carboplatin vs paclitaxel plus carboplatin in advanced non-small cell lung cancer
2008-000977-39Phase 2Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Aug 2008
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial in non-small cell lung cancer (NSCLC) comparing Ixabepilone plus carboplatin with Paclitaxel plus carboplatin (2 arms). Primary endpoints: Progression-free survival in βIII-tubulin-positive subgroup and Progression-free survival in overall study population. Started Aug 2008; status: completed.
02
Drugs
ixabepilonepaclitaxelcarboplatin
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2008-000977-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-000977-39.